Login to Your Account



Other News To Note


Wednesday, September 28, 2011
Talon Therapeutics Inc., of San Mateo, Calif., reported that its new drug application for Marqibo (vincristine sulfate liposomes injection) has been accepted for filing by the FDA under accelerated approval. Prior to the May PDUFA date, Talon plans to begin enrollment in a Phase III confirmatory trial of Marqibo for the treatment of adults, 60 or older, with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription